格隆汇12月8日丨瑞华泰(688323.SH)公布，公司于2025年12月8日收到航科新世纪科技发展（深圳）有 限公司出具的《关于股份变动触及1%刻度的告知函》，2025年11月26日至2025年12月8日期间，航科新 世纪科技发展（深圳）有限公司通过集中竞价的方式减持公司股份100万股，所持有公司股份数量由 4208.31万股减少至4108.31万股，占公司当前总股本的比例由23.38%减少至22.82%，触及1%的整数倍。 ...

瑞华泰公告称，2025年11月26日至12月8日，航科新世纪科技发展（深圳）有限公司通过集中竞价减持 公司股份100万股，持股数由4208.3059万股降至4108.3059万股，占公司总股本比例由23.38%降至 22.82%，触及1%整数倍。本次减持是股东履行减持计划，不触及要约收购，不影响公司无实控人状 态、第一大股东地位、治理结构和持续经营，且未违反承诺。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002585 | 双星新材 | 7.62 | 9.96% | 20.73万 | 1.58亿 | | 301003 | 江苏博云 | 39.34 | 6.41% | 3.00万 | · 1.17 乙 | | 002838 | 道恩股份 | 24.41 | 6.08% | 9.60万 | 2.32亿 1 | | 688669 | 緊石化学 | 22.00 | 5.26% | 3.09万 | 6718.82万 | | 601208 | 东材科技 | 20.76 | 5.22% | 75.56万 | 15.57 乙 | | 600135 | 乐凯胶片 | 8.64 | 4.98% | 44.07万 | 3.81亿 | | 688323 | 瑞华泰 | 18.35 | 4.80% | 18.53万 | 3.35 Z | | 002632 | 道明光学 | 15.67 | 4.47% | 143.97万 | 21.91亿 | | 301019 | 宁波色母 | ...

Core Viewpoint - Haichuang Pharmaceutical's self-developed drug, Deuteroenzalutamide soft capsule, has been included in the national medical insurance drug list, effective from January 1, 2026, marking a significant milestone for the company and the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1][2] Group 1 - Deuteroenzalutamide soft capsule is a first-class new drug developed by Haichuang Pharmaceutical, specifically for treating mCRPC, and is recognized as a second-generation androgen receptor inhibitor [1] - The drug is the first domestically approved innovative medication for adult patients with mCRPC who have progressed after treatment with abiraterone acetate and chemotherapy, and have not previously received new androgen receptor inhibitors [1] - The drug demonstrates superior safety compared to other new endocrine therapies, significantly reducing the incidence of central nervous system adverse events and avoiding rash-related side effects, while also lowering the risk of common complications in elderly patients [1] Group 2 - The inclusion of Deuteroenzalutamide soft capsule in the national medical insurance drug list reflects the recognition of its clinical value, patient benefits, and innovation by the National Healthcare Security Administration [2] - This inclusion is expected to facilitate market promotion of the drug, reduce the financial burden on patients, and enhance drug accessibility [2] - Haichuang Pharmaceutical plans to actively support the implementation of medical insurance policies and continue to promote hospital access and core market coverage to meet patient medication needs more broadly [2]

Core Insights - Polyimide (PI) is a high-performance polymer material known for its exceptional thermal stability, withstanding temperatures from -269℃ to over 500℃, making it crucial in aerospace, flexible displays, and advanced chips [2][5][19] - The PI industry faces significant challenges due to high-end product monopolization by foreign companies, leading to a "bottleneck" in domestic production capabilities [2][10][21] Group 1: Overview of Polyimide - Polyimide is a polymer characterized by the presence of imide rings, synthesized from diamines and dianhydrides [4] - It is recognized as one of the most promising engineering plastics of the 21st century, with applications across various high-tech industries [5][7] Group 2: Polyimide Industry Chain - The PI industry chain follows a "raw material supply - product manufacturing - application" model, with a notable integration of synthesis and product formation [10][26] - The upstream segment includes core monomers and auxiliary materials, with a reliance on imports for high-end monomers [14][15] - The midstream focuses on the manufacturing of various PI products, with significant technical barriers and a concentration of production among a few global leaders [17][18] - The downstream applications span electronics, aerospace, and military sectors, driven by the demand for high-performance materials [23][24] Group 3: Market Supply and Demand - Global PI production capacity increased from approximately 90,000 tons in 2020 to an estimated 110,000 tons by the end of 2023, with a compound annual growth rate (CAGR) of 6.9% [28][30] - The market for PI materials is projected to reach 104.4 billion yuan by 2030, with a CAGR of 6.98% from 2023 to 2030 [37] - In China, the PI production capacity is expected to grow significantly, with a focus on high-end applications, although the country still relies heavily on imports for advanced PI products [42][46] Group 4: Technological Aspects - The production of PI involves complex chemical reactions and requires a deep understanding of polymerization mechanisms and process control [55][57] - Various synthesis methods for PI resins include one-step, two-step, and three-step processes, each with distinct technical requirements [58]

资金流向方面，该股今日全天主力资金净流入2212.47万元。（数据宝） 瑞华泰12月5日龙虎榜 | 买入营业部名称 | 买入金额(万元) | | --- | --- | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 1868.42 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 1701.15 | | 东莞证券股份有限公司东莞长安分公司 | 1148.66 | | 中信证券股份有限公司上海分公司 | 1085.44 | | 瑞银证券有限责任公司上海花园石桥路证券营业部 | 1049.37 | | 卖出营业部名称 | 卖出金额(万元) | | 世纪证券有限责任公司江西分公司 | 1770.82 | | 机构专用 | 923.65 | | 高盛(中国)证券有限责任公司上海浦东新区世纪大道证券营业部 | 811.10 | | 财达证券股份有限公司邯郸人民西路证券营业部 | 686.99 | | 摩根大通证券(中国)有限公司上海银城中路证券营业部 | 670.66 | 12月5日瑞华泰（688323）收盘价17.51元，收盘上涨16.58%，全天换手率7.83%，振幅17.91% ...

12月5日，A股震荡上攻，题材股轮动加快，市场逾4300股上涨；午后非银金融板块放量拉升。 截至收盘，上证指数涨0.7%，深证成指涨1.08%，创业板指涨1.36%。 1.两市主力资金净流入近18亿元 今日沪深两市主力资金开盘净流出82.49亿元，尾盘净流入21.94亿元，全天净流入17.75亿元。 | | | 沪深两市最近五个交易日主力资金流向情况 (亿元) | | | | --- | --- | --- | --- | --- | | 日期 | 净流入金额 | 开盘净流入 | 尾盘净流入 | 超大单净买入 | | 2025-12-5 | 17.75 | -82.49 | 21.94 | 81.12 | | 2025-12-4 | -214.71 | -121.97 | -35.67 | -69.28 | | 2025-12-3 | -452.50 | -107.61 | -37.35 | -214.99 | | 2025-12-2 | -310.83 | -136.81 | -36.65 | -194.57 | | 2025-12-1 | -3.43 | -9.06 | 10.36 | 40.37 | 2 ...

证券日报网讯12月4日，瑞华泰在互动平台回答投资者提问时表示，在新能源电池领域，公司目前在复 合集流体、负极PI粘结剂等方面，积极配合下游客户的研发及试用诉求。后续进展情况，公司将按照相 关法律法规规定，及时履行信息披露义务。 ...

Core Viewpoint - Ruhi Tai is positioned at the upstream of the electronic industry chain, with products widely used in flexible circuit boards and flexible electronic substrates, ultimately applicable to various smart terminals, including AR glasses as a consumer electronics application scenario [1] Group 1 - The company operates in the upstream segment of the electronic industry chain [1] - Products are extensively utilized in flexible circuit boards and flexible electronic substrates [1] - The end applications of these products include various smart terminals, highlighting AR glasses as a specific consumer electronics application [1]

（记者 王晓波） 瑞华泰（688323.SH）12月4日在投资者互动平台表示，公司处于电子产业链最上游，产品广泛应用于 柔性线路板及柔性电子基材，最终可应用于各类智慧终端，AR眼镜是消费电子终端的应用场景之一。 每经AI快讯，有投资者在投资者互动平台提问：公司的产品有用于智能穿戴设备AR眼镜否？ ...